Seed Health is a technology company.
Seed Health has raised $55.0M across 2 funding rounds.
Key people at Seed Health.
Seed Health has raised $55.0M in total across 2 funding rounds.
Key people at Seed Health.
Seed Health is a microbiome science company founded in 2016 that develops science-backed probiotics and synbiotics for human health, alongside environmental solutions, operating in the biotechnology sector.[1][2][3] Its flagship products, marketed under the Seed brand, include DS-01® Daily Synbiotic for adults targeting whole-body health, PDS-08® Pediatric Daily Synbiotic for kids and teens, and VS-01™ Vaginal Synbiotic, addressing gut, brain, skin, and vaginal health through multi-strain formulations.[3][5] The company serves consumers via direct-to-consumer, Amazon, and Target retail channels, solving the problem of ineffective, low-quality probiotics by using advanced microbial genomics, ultra-deep sequencing, and human-centric clinical data to deliver targeted microbiome interventions.[2][3][4] Seed Health has raised $43.75M in funding, achieved profitability, and seen over 500% revenue growth in the past three years, becoming Target's fastest-growing probiotics brand amid a $2.05B U.S. probiotic market in 2024.[1][4]
Seed Health was co-founded in 2016 in Venice, California, by Ara Katz and Raja Dhir, who spent years researching the microbiome after recognizing its untapped potential despite early skepticism in Silicon Valley.[4] Katz and Dhir focused on reinventing probiotics as a consumer product rather than pitching pure microbiome science, conducting extensive foundational work on product rigor and branding before fundraising in 2017 and launching their first commercial product, DS-01, in 2018.[4] Early traction built through a direct-to-consumer model, evolving into retail partnerships like Target and Amazon, where DS-01 now ranks among Amazon's top five probiotics; a pivotal moment came with PDS-08's 2022 launch as a multi-strain synbiotic.[1][4] This humanizes their journey from microbiome pioneers navigating investor doubt to profitability via science-driven innovation.[4]
Seed Health rides the surging microbiome trend, fueled by consumer and scientific recognition of gut bacteria's role in overall health, amid probiotic sales hitting $2.05B in 2024.[4] Timing aligns with advanced sequencing tech enabling precise interventions, positioning Seed against competitors like Brightseed in bioactive discovery.[1][3] Market forces favoring it include retail expansion (e.g., Target dominance) and profitability in a DTC-to-B2B shift, influencing the ecosystem by elevating probiotics from commoditized supplements to clinically-studied therapeutics and inspiring biotech crossovers into environmental applications.[4]
Seed Health's trajectory points to pipeline expansion in gut-brain (e.g., GBH-01 prebiotic), dermatological (MH-01 synbiotic), and SeedLabs environmental programs, capitalizing on aging populations and sustainability demands.[3] Trends like multi-omics integration and regulatory clarity for synbiotics will accelerate growth, potentially evolving its influence from consumer leader to microbiome therapeutics powerhouse. This builds on its science-driven reinvention of probiotics, promising scaled impact for human and planetary health.[2][3][4]
Seed Health has raised $55.0M in total across 2 funding rounds.
Seed Health's investors include Alumni Ventures, Anderson Angels, Vasudev Bailey, Artis Ventures (AV), Modern Venture Partners, Rebel Fund, Daniel Rothman, Endeavor Venture Funds, Polaris Partners, Venrock.
Seed Health has raised $55.0M across 2 funding rounds. Most recently, it raised $40.0M Series A in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $40.0M Series A | Alumni Ventures, Anderson Angels, Vasudev Bailey, Artis Ventures (AV), Modern Venture Partners, Rebel Fund, Daniel Rothman | |
| Mar 1, 2021 | $15.0M Series A | Endeavor Venture Funds, Polaris Partners, Venrock |
